PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma

被引:3
|
作者
Sahinli, Hayriye [1 ]
Akyurek, Nalan [2 ]
Yilmaz, Mukaddes [3 ]
Kandemir, Olcay [4 ]
Duran, Ayse Ocak [5 ]
Kulacoglu, Sezer [6 ]
Ucar, Gokhan [7 ]
Acar, Elif [2 ]
Ozet, Ahmet [3 ]
Gumus, Mahmut [8 ]
Oksuzoglu, O. Berna C. [5 ]
Ozdemir, Nuriye Y. [7 ]
机构
[1] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Oncol, Ankara, Turkey
[2] Gazi Univ, Dept Pathol, Med Hosp, Ankara, Turkey
[3] Gazi Univ, Dept Oncol, Med Univ Hosp, Ankara, Turkey
[4] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Dept Pathol, Ankara, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Dept Oncol, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Dept Pathol, Ankara, Turkey
[7] Ankara Numune Training & Res Hosp, Dept Oncol, Ankara, Turkey
[8] Istanbul Medipol Univ, Dept Oncol, Med Sch, Istanbul, Turkey
关键词
Nasopharyngeal carcinoma; prognosis; programmed death ligand-1; TUMOR-INFILTRATING LYMPHOCYTES; PROGRAMMED DEATH LIGAND-1; GASTRIC-CANCER; DISTINCT EXPRESSION; T-CELLS; MICROENVIRONMENT; CHEMORADIOTHERAPY; RADIOTHERAPY; SURVIVAL; PHASE;
D O I
10.4103/ijc.IJC_459_19
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Programmed death-ligand 1 (PD-L1) has been determined as a reliable prognostic factor for various malignancies. In this study, we aimed to determine the prognostic effect of PD-L1 expression in tumor-infiltrating immune cells (TIICs) of nasopharyngeal carcinoma (NPC) patients. Methods: Seventy patients diagnosed with non-metastatic NPC were included in the study. PD-L1 expression on immune cells was analyzed by immunohistochemical method. Patients were categorized into two groups according to the PD-L1 expression level in TIICs (level of PD-L1 staining >= 5% positive vs <5% negative). Results: Median follow-up period was 34 months (range = 1 - 188). 1 and 2 years survival rate were found as 75% and 63% in PD-L1 negative TIICs group (47%), and 85% and 83% in PD-L1 positive TIICs group (53%), respectively. PD-L1 positivity in immune cells (ICs) was detected in 53% of the patients. The survival rate was found better in the PD- L1 positive group compared to the negative group (P = 0.049). Discussion: In conclusion, the survival rate was found significantly better in the PD-L1 positive TIICs group, compared to the negative group.
引用
收藏
页码:561 / 566
页数:6
相关论文
共 50 条
  • [1] PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients
    Sznurkowski, Jacek J.
    Zawrocki, Anton
    Sznurkowska, Katarzyna
    Peksa, Rafal
    Biernat, Wojciech
    ONCOTARGET, 2017, 8 (52): : 89903 - 89912
  • [2] High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma
    Zhong, Qiaofeng
    Shou, Jianzhong
    Ying, Jianming
    Ling, Yun
    Yu, Yue
    Shen, Zhirong
    Zhang, Yun
    Li, Ning
    Shi, Yuankai
    Zhou, Aiping
    FUTURE ONCOLOGY, 2021, 17 (22) : 2893 - 2905
  • [3] Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes
    Zhu, Qian
    Cai, Mu-Yan
    Chen, Chang-Long
    Hu, Hao
    Lin, Huan-Xin
    Li, Min
    Weng, De-Sheng
    Zhao, Jing-Jing
    Guo, Ling
    Xia, Jian-Chuan
    ONCOIMMUNOLOGY, 2017, 6 (05):
  • [4] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma
    Mocan, Lavinia Patricia
    Craciun, Rares
    Grapa, Cristiana
    Melincovici, Carmen Stanca
    Rusu, Ioana
    Al Hajjar, Nadim
    Sparchez, Zeno
    Leucuta, Daniel
    Ilies, Maria
    Sparchez, Mihaela
    Mocan, Tudor
    Mihu, Carmen Mihaela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (04) : 1003 - 1014
  • [5] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
    Kim, Hye Ryun
    Ha, Sang-Jun
    Hong, Min Hee
    Heo, Su Jin
    Koh, Yoon Woo
    Choi, Eun Chang
    Kim, Eun Kyung
    Pyo, Kyoung Ho
    Jung, Inkyung
    Seo, Daekwan
    Choi, Jaewoo
    Cho, Byoung Chul
    Yoon, Sun Och
    SCIENTIFIC REPORTS, 2016, 6
  • [6] PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma
    Sughayer, Maher A.
    Dabbagh, Tamara Z.
    Battah, Abdelkader H.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (10) : 748 - 754
  • [7] Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis
    Kim, Younghoon
    Xianyu, Wen
    Cho, Nam Yun
    Kang, Gyeong Hoon
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2018, 33 (04): : 467 - 474
  • [8] PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
    Wu, Yanhua
    Cao, Donghui
    Qu, Limei
    Cao, Xueyuan
    Jia, Zhifang
    Zhao, Tiancheng
    Wang, Quan
    Jiang, Jing
    ONCOTARGET, 2017, 8 (38) : 64066 - 64082
  • [9] The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma
    Guenole, Morgan
    Benigni, Paolo
    Bourbonne, Vincent
    Lucia, Francois
    Legoupil, Delphine
    Pradier, Olivier
    Misery, Laurent
    Uguen, Arnaud
    Schick, Ulrike
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2569 - 2578
  • [10] PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
    Kim, Ki Hyung
    Choi, Kyung Un
    Kim, Ahrong
    Lee, So Jung
    Lee, Jung Hee
    Suh, Dong Soo
    Kwon, Byung-su
    Hwang, Chungsu
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)